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1,3,5-TriazineAbstract A novel series of hybrid 4-aminoquinolines-1,3,5-triazine were synthesized by means of
aromatic nucleophilic displacement of chlorine atoms of 2,4,6-trichloro-1,3,5-triazine. Afforded title
analogs were subsequently characterised by elemental analysis, FT-IR, 1H NMR, 13C NMR and
mass spectroscopy and subjected to screening against chloroquine sensitive RKL2 strain of
Plasmodium falciparum in 96 well-microtitre plates. However, synthesized derivatives exhibit mild
to moderate antimalarial activity and acute toxicity studies of the most active (6a and 6g) com-
pounds were shown to have no signiﬁcant change in body insight and toxic sign.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Multidrug resistant Plasmodium parasites are the biggest ther-
apeutic challenge to health care in most malaria-endemic areas
speciﬁcally tropical and sub-tropical areas (Kremsner and
Krishna, 2004). Resistance to former ﬁrst-line treatment,
chloroquine and sulfadoxine-pyrimethamine is becoming mostapparent in Plasmodium falciparum species (Marfurt et al.,
2010). Moreover, it has rendered monotherapy for malaria
useless in most parts of the world (Guidelines for the treatment
of malaria, 2010). To improve efﬁcacy and delayed onset of
resistance, the World Health Organization began recommend-
ing the use of Artemisinin Combination Therapies (ACTs)
since 2005 (Rogerson and Menendez, 2006). Currently, ACTs
demonstrate excellent clinical efﬁcacy, paradoxically the his-
tory of antimalarial chemotherapy predicts that it is a matter
of time before parasitic resistance re-emerges (Ekland and Fi-
dock, 2008). Nevertheless, safe and cost effective new antima-
larial agents are urgently needed to treat malaria (Guerin et al.,
2002).
One important pipeline approach is the new generation of
hybrid molecules against both chloroquine sensitive and resis-
tant strains of P. falciparum by diverse functionalization of
Figure 1 Structure of (a) chloroquine, (b) cycloguanil and (c) hybrid 4-aminoquinoline-1,3,5-triazine derivatives.
Figure 2 Hybrid 4-aminoquinoline-1,3,5-triazine derivatives
(6a–g).
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atives (Chiyanzu et al., 2005), b-carbolines (Gupta et al., 2008),
the peroxide based trioxaquine derivatives (Singh et al., 2004)
etc. The Structure activity relationships (SARs) of 4-amino-
quinolines with propyl side chain [HN(CH2)3NH–] exhibit
most potent activity against chloroquine-susceptible P. falcipa-
rum (Kgokong et al., 2008). Encouraged by these observations
and in continuation of our investigation in search of new and
effective pharmacophores from 1,3,5-triazine (Singh et al., in
press; Gahtori et al., 2009), we herein report a new series of hy-
brid 4-aminoquinoline-1,3,5-triazine (Fig. 1c), as a core bioac-
tive lead fragment derived from chloroquine (Fig. 1a) andcycloguanil (Fig. 1b) to obtain seven novel hybrid 4-amino-
quinoline-1,3,5-triazine derivatives (6a–6g) (Fig. 2).
2. Results
A series of hybrid 7-chloro-4-aminoquinoline substituted
1,3,5-triazines derivatives 6a–g were synthesized, characterized
and found in agreement with spectroscopic analysis. IR spectra
of the all products 6a–g nearer at 3350 cm1 is due to the
primary amino groups, where as the secondary –NH linker
between 4-aminoquinoline and 1,3,5-triazine appears in the
region 3214–3140 cm1. The strong absorption bands at
850–670 cm1 conﬁrm the existence of aromatic skeleton.
The 1H NMR spectrums report a signal corresponding to
the quinolyl proton at 6.46–10.01 ppm. 13C NMR of the
carbon atom of 1,3,5-triazine was detected at 152.30–
168.61 ppm. The tested compounds, 6e, 6f and 6g have shown
good in vitro antimalarial efﬁcacy under similar experimental
conditions with reference to the standard drug chloroquine.
2.1. Acute toxicity
The three active hybrid 4-aminoquinoline-1,3,5-triazine deriv-
atives 6e, 6f and 6g, were further tested for acute toxicity test-
ing-Up and Down procedure (UDP) as recommended by the
Organization for Economic Co-operation and Development
(OECD) (Guidelines for the Testing of Chemicals, 2006).
These test compounds at a test dose of 2000 mg/kg for 48 h
intervals and serially for a total of 14 days have exhibited no
signiﬁcant changes in body weight and toxic signs.
3. Discussion
The antimalarial screening result reﬂects that the compounds
6e, 6f and 6g possessing aromatic group along with chloro,
Synthesis, antimalarial activity of 1,3,5-triazines S627ﬂuoro and morpholino substitution have shown comparatively
good in vitro antimalarial activity ranges from 47.5 to 56 in
comparison to chloroquine under similar test conditions. Out
of seven evaluated compounds, N2,N4-bis (3-chloro-4-ﬂuoro-
phenyl)-N6-(3-(7chloroquinolin-4-ylamino) propyl)-1,3,5-tri-
azine-2,4,6-triamine (6f) was found to be the most active
against chloroquine sensitive strain and the cut off value
(LD50 > 2000 mg/kg) for 6e, 6f and 6g was recorded via oral
administration proves its efﬁcacy. These new hybrid series of
4-aminoquinoline-1,3,5-triazine were found to be less effective
than chloroquine, however their in vitro results prove these
new hybrids as a promising model for further optimization
work in malarial chemotherapy.
4. Experimental
All commercially available solvents and reagents were of AR
grade and used without further puriﬁcation. Melting points
were determined on a Veego, MPI melting point apparatus
and are uncorrected. UVmax (DMSO) were recorded on
Shimadzu UV-1700 and FT-IR (2.0 cm1, ﬂat, smooth, abex)
were taken on Perkin Elmer RX-I Spectrophotometer. 1H
NMR spectra were recorded on Bruker Avance II 400 NMR
and 13C NMR spectra on Bruker Avance II 100 NMR spec-
trometer in DMSO-d6 using TMS as the internal standard.
Mass spectra were obtained on VG-AUTOSPEC spectrometer
equipped with electrospray ionization (ESI) sources. Elemental
analysis was carried out on Vario EL-III CHNOS element or
analyzer.Scheme 1 Reagents and conditions: (a) Reﬂux/80 C/1 h fol-
lowed by reﬂux at 6–8 h at 120–130 C.
Scheme 2 Reagents and conditions: (a) R–H (a–g) distinguished am
dioxane 120–130 C 5–6 h.4.1. Preparation of parasites
The chloroquine sensitive RKL-2 strain (Raurkela, Orissa,
India) of P. falciparum were routinely maintained in stock cul-
tures in medium RPMI-1640 supplemented with 25 mmol
HEPES, 1% D-glucose, 0.23% sodium bicarbonate and 10%
heat inactivated human serum. The asynchronous parasites
of P. falciparum were synchronized after 5% D-sorbitol
treatment to obtain only the ring stage parasitized cells. For
carrying out the assay, the initial ring stage parasitaemia of
0.8–1.5% at 3% hematocrit in a total volume of 200 lL of
medium RPMI-1640 was uniformly maintained.
4.2. In vitro antimalarial efﬁcacy test
The in vitro antimalarial assay was carried out according to
microassay of Rieckmann et al. (1978) in 96 well-microtitre
plates, with minor modiﬁcations. A stock solution of 5 mg/
mL of each of the test samples was prepared in DMSO and
subsequent dilutions were prepared with the culture medium.
The test compounds in 20 lL volume concentration at 50 lg/
mL in a duplicate well were incubated with parasitized cell
preparation at 37 C in a candle jar. After 36–40 h of incuba-
tion, the blood smears were prepared from each well and
stained with Giemsa stain. The level of parasitemia in terms
of % dead rings along with Schizonts was determined by
counting a total of 100 asexual parasites (both live and alive)
microscopically using chloroquine as the reference drug.
4.3. Synthesis and structural investigation
The desired compounds 3 and 6a–g were synthesised by the
synthetic protocols as outlined in Schemes 1 and 2, respec-
tively. Synthesis of compound (3) was achieved by the nucleo-
philic substitution of 1,3-diaminopropane (2) at the 4-Cl atom
of 4,7-dichloroquinoline (1). The synthesis of di-substituted
1,3,5-triazines 5(a–g) were accomplished by the nucleophilic
substitution of the Cl atom of the 1,3,5-triazines (4) with differ-
ent primary amines (a–g) as shown in Fig. 2. Finally title ana-
logs 6(a–g) were synthesized by incorporating di-substitutedines, (b) 1,4 dioxane 0–5 C 1 h, 40–45 C 3 h, KHCO3, (c) 1,4
S628 H.R. Bhat et al.1,3,5-triazine moiety 5(a–g) with the side chain attached to
4-aminoquinoline pharmacophore (3).
4.4. Synthesis of N1-(7-chloro-quinolin-4-yl)-propane-1,3-
diamine (3)
The compound 3 is prepared by the published procedure
(De et al., 1997) to yield an off-white solid, characterized by
the following physicochemical properties % yield: 83.2, mp:
77–78 C; FTIR (cm1): 3346, 3333 (sym. & asym. N–Hstretch,
–NH2), 3253 (N–Hstretch >NH), 2987, 2893 (C–Hstretch,
>CH2), 2029, 1950, 1636, 1603, 1571 (N–Hbend), 1464, 1360,
1320, 1240, 1190 (C–Hstretch), 1090, 910, 850, 800, 760, 610;
1H NMR (400 MHz, DMSO-d6): d 8.29–8.14 (m, 1H, quino-
lyl), d 8.04–8.02 (d, 1H, J= 9.20 Hz, quinolyl), d 7.90–7.89
(d, 1H, J= 6.00 Hz, quinolyl), d 7.77–7.56 (dd, 1H,
J= 18.00, 18.00 Hz, quinolyl), d 7.51 (s, 2H, NH), d
7.35–7.33 (d, 1H, J= 7.60 Hz, quinolyl), d 7.25 (br s, 1H,
NH), d 6.55–6.08 (m, 2H, CH), d 3.32–3.27 (t, 2H,
J= 9.6 Hz, CH2), d 2.81–2.71 (t, 2H, J= 19.2 Hz, CH2);
13C NMR (100 MHz, DMSO-d6): d 176.94, 152.53, 150.75,
146.89, 136.79, 134.26, 127.59, 125.07, 117.72, 109.54,
103.24, 99.14, 44.67, 40.46, 37.95, 27.65, 25.07; Mass: 236.3
[M+H]+.
4.5. General procedure for the synthesis of di-substituted 1,3,5-
triazine derivative 5a–g
These derivatives were synthesized according to the published
procedures (Thruston et al., 1951; Richard et al., 2007). Finally
obtained reaction mixture was poured into crushed ice. The so-
lid separated out was ﬁltered, washed with water and recrystal-
lized from different solvents to yield 5a–g.
4.5.1. 6-Chloro-N2,N4-di-isopropyl-1,3,5-triazine-2,4-diamine
(5a)
%Yield: 84.11, mp: 86–88 C; FTIR (cm1): 2969.66
(C–Hstretch), 1582.26 (N–Hbend), 1324.20 (N–Hstretch, >NH),
1019.08 (C–Hbend out of plane);
1H NMR (400 MHz, DMSO-
d6): d 1.35 (d, J= 6.9 Hz, 12H, 4· CH3), 2.04 (m, 2H, 2·
CH), 3.42 (t, 2H, 2· NH); 13C NMR (100 MHz, DMSO-d6):
d 20.53, 47.35, 163.56, 168.96; Mass: 229.11 (M+H)+; Anal.
Calcd. for C9H16ClN5: C, 47.06; H, 7.02; N, 30.49. Found:
C, 47.04; H, 6.99; N, 30.50.
4.5.2. 6-Chloro-2,4-dimorpholino-1,3,5-triazine (5b)
%Yield: 73.32, mp: 132–135 C; FTIR (KBr) cm1 2966.61,
1574.98–1451.24, 1362.21, 1116.51; H1 NMR (400 MHz,
CDCl3) d 3.70 (t, J = 4.9 Hz, 8H, 4· CH2–N), 3.78 (t, 8H,
4· CH2–O); C13 NMR (100 MHz, CDCl3) 43.86, 66.56,
164.48, 169.69; Mass: 286.10 (M+H)+; Anal. Calcd. for
C11H16ClN5O2: C, 46.24; H, 5.64; N, 24.51. Found: C, 46.28;
H, 5.58; N, 24.56.
4.5.3. 6-Chloro-N2,N4-bis(4-nitrophenyl)-1,3,5-triazine-2,4-
diamine (5c)
%Yield: 84.16; mp: 86–88 C; FTIR (cm1) 3055.70, 1548.28–
1446.06, 1342.89, 1079.19; 1H NMR (400 MHz, CDCl3) d 7.40
(t, 4H, 4· ‚CH–), 7.32 (t, 4H, 4· ‚CH–), 3.62 (d, 2H,
2· –NH); 13C NMR (100 MHz, CDCl3) 126.23, 131.36 (Ar–
C), 143.16 (Ar–C–NO2), 148.26 (Ar–C–NH), 168.85 (Ar–C–Cl), 173.56 (Ar–C–N, s-triazine); Mass: 388.10 (M+H)+;
Anal. Calcd. for C15H10ClN7O4: C, 46.46; H, 2.60; N, 25.29.
Found: C, 46.42; H, 2.62; N, 25.28.
4.5.4. 6-Chloro-N2,N4-bis(2-cyclohexylethyl)-1,3,5-triazine-
2,4-diamine (5d)
%Yield: 95.12, mp: 145–147 C; FTIR (cm1) 3058.50,
2964.12, 1549.12, 1446.06, 1342.89, 1076.11; 1H NMR
(400 MHz, CDCl3) d 3.62 (q, 4H, 2· –CH2 ethyl), 2.62 (m,
2H, 2· –CH cyclohexyl), 1.48(m, 8H, –CH2 cyclohexyl), 1.42
(m, 8H, –CH2 cyclohexyl), 1.24 (t, 6H, 2·CH3 ethyl); 13C
NMR (100 MHz, CDCl3) 29.23, 25.26, 33.18 (cyclohexyl),
18.18, 52.12 (ethyl), 158.26 (Ar–C–NH), 169.65 (Ar–C–Cl),
172.16 (Ar–C–N, s-triazine); Mass: 367.25 (M+H)+; Anal.
Calcd. for C19H32ClN5: C, 62.36; H, 8.81; N, 19.14. Found:
C, 62.34; H, 8.90; N, 19.16.
4.5.5. 6-Chloro-N2,N4-bis(4-morpholinylphenyl)-1,3,5-triazine-
2,4-diamine (5e)
%Yield: 85.22; mp: 108–110 C; FTIR (cm1) 3057.70,
2965.12, 1549.18,1447.16, 1342.91, 1076.12, 974.13; 1H NMR
(400 MHz, CDCl3) d 7.62 (t, 4H, 2· –CH), 6.75 (t, 2H,
–CH), 6.65 (t, 4H, 2· –CH), 3.84 (m, 8H, –CH2), 3.31(m,
8H, –CH2);
13C NMR (100 MHz, CDCl3) 71.23, 78.25
(C-morpholine), 113.46, 118.36, 128.26 (Ar–C), 168.85 (Ar–
C–Cl), 172.24 (Ar–C–N, s-triazine); Mass: 468.18 (M+H)+;
Anal. Calcd. for C23H26ClN7O2: C, 59.03; H, 5.60; N, 20.95.
Found: C, 59.05; H, 5.61; N, 20.95.
4.5.6. 6-Chloro-N2,N4-bis(3-chloro-4-ﬂurophenyl)-1,3,5-
triazine-2,4-diamine (5f)
%Yield: 91.86; mp: 152–155 C; FTIR (cm1) 3052.32,
1549.58, 1453.25, 1345.91, 978.21; 1H NMR (400 MHz,
CDCl3) d 6.98 (d, 2H, 2· –CH), 6.54 (d, 2H, 2· –CH), 6.84
(d, 2H, 2· –CH), 4.66 (d, 2H, –NH); 13C NMR (100 MHz,
CDCl3) 118.11, 122.13, 152.13 (Ar–C), 171.19 (Ar–C–Cl),
179.54 (Ar–C–N, s-triazine); Mass: 401.03 (M+H)+; Anal.
Calcd. for C15H8Cl3F2N5: C, 44.75; H, 2.00; N, 17.39. Found:
C, 44.74; H, 2.01; N, 17.40.
4.5.7. 6-Chloro-N2,N4-bis(4-ﬂurophenyl)-1,3,5-triazine-2,4-
diamine (5g)
%Yield: 88.86; mp: 143–145 C; FTIR (cm1) 3054.72,
1548.58, 1448.25, 1342.91, 978.16; 1H NMR (400 MHz,
CDCl3) d 7.68 (d, 4H, 2· –CH), 7.14 (d, 4H, 2· –CH), 4.84
(t, 2H, –NH); 13C NMR (100 MHz, CDCl3) 117.46, 118.11
(Ar–C), 153.43 (Ar–C–F), 172.89 (Ar–C–Cl), 181.24 (Ar–C–
N, s-triazine); Mass: 334.10 (M+H)+; Anal. Calcd. for
C15H10ClF2N5: C, 53.99; H, 3.02; Cl, 10.62; F, 11.39; N,
20.99. Found: C, 54.00; H, 3.01; Cl, 10.64; F, 11.35; N,
20.98.
4.6. General procedure for the synthesis of compounds (6a–g)
A mixture of 3 (0.01 M) and 5a–g (0.01 M) were dissolved in
acetone (50 mL) and the reaction mixture was reﬂuxed for
6–8 h. At a regular interval 10% sodium carbonate solution
was added to neutralize hydrochloric acid evolved during the
reaction. Then the reaction mixture was poured into crushed
ice. The product separated was ﬁltered, washed with water
and recrystallized from ethanol (see Table 1).
Table 1 In vitro antimalarial activity of the synthesized
compounds 6a–g.
Compoundsa Antimalarial activity
(% dead rings + schizontsb)
6a 26.5
6b 17.0
6c 10.0
6d 8.5
6e 47.5
6f 56.0
6g 51.5
Chloroquine 50.5
a Dose for synthesized compounds 50 lg/ml whereas for chloro-
quine 0.4 lg/mL.
b Mean of two replicates counted against 100 asexual parasites
per replicate.
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diisopropyl-1,3,5. triazine-2,4,6-triamine (6a)
%Yield 64.86; mp: 184–186 C; UV kmax (DMSO): 334.0 nm;
FTIR (cm1): 3251 (N–Hstretch, >NH), 2969 (C–Hstretch), 2872
(C–Hstretch,>CH2), 1554 (N–Hbend), 1461 (>C‚C<stretch),
1383 (Isopropyl group), 1364,1338, 1313 (C–Hstretch), 1243 (C–
Hbending), 1167 (C–Hstretch), 1129, 1080 (C–Nstretch), 1018, 967,
891 (C–Hbend out of plane), 851, 805 (C–Hstretch out of plane), 761,
692 (C–Hbend out of plane), 557, 497;
1H NMR (400 MHz,
DMSO-d6): d 8.28–8.26 (d, 1H, J= 9.60 Hz, quinolyl), d 7.75
(s, 1H,NH), d 7.68–7.66 (d, 1H, J= 7.60 Hz, quinolyl), d 7.57
(s, 1H, NH), d 7.40–7.30 (d, 1H, J= 40.80 Hz, quinolyl), d
6.47–6.39 (d, 1H, J= 32.00 Hz, Ar–H), d 6.25–6.00 (d, 1H,
J= 32.00 Hz, Ar–H), d 4.38–4.14 (d, 1H, J= 96.80 Hz, CH),
d 3.98–3.96 (d, 2H, CH2), d 3.74 (s, 2H, CH2), d 3.39–3.27 (m,
2H, CH2), d 2.03–1.83 (d, 1H, J= 80.00 Hz, Isopropyl, CH3),
d 1.69 (s, 1H, NH); 13C NMR (100 MHz, DMSO-d6): d
168.61, 166.26, 165.40, 165.18, 164.93, 164.56, 152.29, 150.55,
149.51, 133.83, 127.90, 124.50, 124.44, 117.95, 99.17, 99.02,
42.49, 42.28, 42.06, 41.29, 40.56, 40.35, 40.14, 39.93, 39.51,
39.31, 38.14, 28.48, 26.90, 23.15, 22.74, 22.62, 22.38; Mass:
429.28 (M+H)+; Anal. Calcd. for C21H29ClN8: C, 58.80; H,
6.81; N, 26.12 Found: C, 58.69; H, 6.63; N, 26.34.
4.6.2. N2-(3-(7-chloroquinolin-4-ylamino)propyl)-4,6-
dimorpholino-1,3,5. triazine-2-amine (6b)
%Yield: 73.0; mp: 207–209 C; UV kmax (DMSO): 337.0 nm;
FTIR (cm1): 3354 (N–Hstretch, >NH), 2959 (C–Hstretch,
>CH2), 2853 (C–Hstretch), 1583 (N–Hbend), 1541 (C‚Ostretch),
1481 (>C‚C<ring stretch), 1441, 1361, 1330, 1303, 1286, 1255,
1213 (C–Hin plane bend), 1136 (C–Hstretch), 1110, 1067
(C–Nstretch), 1005 (C–Ostretch), 906, 855 (C–Hstretch out of plane),
805, 765 (C–Hbend out of plane),737, 639 (C–Hbend), 544;
1H
NMR (400 MHz, DMSO-d6): d 8.33–8.32 (d, 1H,
J= 4.80 Hz, quinolyl), d 8.29–8.27 (d, 1H, J= 8.80 Hz,
quinolyl), d 8.23–8.21 (d, 1H, J= 8.80 Hz, quinolyl, d 7.75
(br s, 1H, NH), d 741–7.39 (d, 1H, J= 9.60 Hz, quinolyl), d
7.33 (br s, 1H, NH), d 6.90–6.88 (d, 1H, J= 7.60 Hz, Ar–
H), d 6.46–6.44 (d, 1H, J= 8.80 Hz, quinolyl), d 6.40–6.39
(d, 1H, J= 6.40 Hz, morpholine CH), d 6.31 (br s, 1H,
morpholine NH), d 3.55 (s, 1H, CH), d 3.39–3.32 (d, 2H,
CH2), d 2.47 (s, 2H, CH2), d 2.036–1.828 (m, 2H, CH2);
13C
NMR (100 MHz, DMSO-d6): d 166.17, 165.17, 152.34,150.54, 150.48, 149.55, 133.81, 127.93, 124.65, 124.44, 117.94,
99.19, 99.06, 66.51, 66.35, 43.70, 43.64, 43.48, 40.36, 40.16,
39.95, 39.74, 39.53, 39.32, 28.34, 26.88; Mass: 485.2
(M+H)+; Anal. Calcd. for C23H29ClN8O2, C, 56.96; H,
6.03; N, 23.10, Found: C, 57.00; H, 6.01; N, 22.98.
4.6.3. N2-(3-(7-Chloroquinolin-4ylamino)propyl)-N4,N6-bis(4-
nitrophenyl)-1,3,5-triazine -2,4,6-triamine (6c)
%Yield: 66.67; mp: 230–232 C; UV kmax (DMSO): 373.0 nm;
FTIR (cm1): 3214 (N–Hstretch, >NH), 2923 (C–Hstretch,
>CH2), 1580 (N–Hbend), 1530, 1494 (>C‚C<ringstretch),
1418 (C–O–Hbend), 1369, 1301 (C‚Ostretch), 1245, 1177, 1135
(C–Hstretch), 1108, 899, 847 (C–Hstretch out of plane), 804, 750
(C–Hbend out of plane), 691 (C–Hbend), 628,492;
1H NMR
(400 MHz, DMSO-d6): d 10.01–9.93 (d, 2H, J= 33.20 Hz,
quinolyl –H), d 9.68–9.60 (d, 2H, J= 30.00 Hz, quinolyl
–H), d 8.53 (s,1H, NH), d 8.33–8.26 (d, 1H, J= 26.80 Hz, qui-
nolyl), d 8.11–8.05 (d, 1H, J= 21.20 Hz, quinolyl), d 7.92–7.74
(d, 1H, J= 69.20 Hz, quinolyl), d 7.42–7.37 (d, 1H,
J= 21.20 Hz, quinolyl), d 7.12–7.07 (d, 1H, J= 20.80 Hz,
quinolyl), d 6.71 (s, 1H, NH), d 6.58–6.47 (d, 1H,
J= 45.20 Hz, Ar–H), d 5.84–5.83 (d, 2H, J= 56.40 Hz,
CH2), d 3.52–3.38 (d, 2H, CH2), d 2.03–1.92 (d, 2H,
J= 41.20 Hz,; 13C NMR (100 MHz, DMSO-d6): d 152.31,
151.03, 149.45, 134.02, 127.91, 124.55, 117.92, 99.22, 40.56,
40.37, 40.16, 39.95, 39.75, 39.54, 39.33; Mass: 587.2 (4.45)
(M+H)+, 324.1 (100), 397.1 (72.64) 399.1 (49.09). Anal.
Calcd. for C27H23ClN10O4: C, 55.25; H, 3.95; N, 23.86, Found:
C, 55.23; H, 3.91; N, 23.89.
4.6.4. N2-(3-(7-Chloroquinolin-4-ylamino)propyl)-N4,N6-
bis(2-cyclohexylethyl)-1,3,5-triazine-2,4,6-triamine (6d)
%Yield: 65.53; mp: 252–254 C; UV kmax (DMSO): 269.0 nm;
FTIR (cm1): 3242 (N–Hstretch, >NH), 2924 (C–Hstretch,
>CH2), 2852 (C–Hstretch), 2872, 2364, 1579 (N–Hbend), 1463
(n-hexene), 1364, 1201, 1135 (C–Hstretch), 899, 851 (C–Hstretch
out of plane), 808, 598;
1H NMR (400 MHz, DMSO-d6): d
8.32–8.24 (d, 1H, J= 30.40 Hz, quinolyl), d 8.03 (d, 1H,
J= 2.08 Hz, quinolyl), d 7.75–7.55 (d, 1H, J= 80.00 Hz, qui-
nolyl), d 7.39–7.23 (d, 1H, J= 64.00 Hz, cyclohexyl), d 6.46–
6.40 (d, 1H, J= 26.00 Hz, Ar–H), d 3.58 (s, 2H, CH2), d
2.50–2.46 (d, 1H, CH), d 1.63 (s, 2H, CH2), d 1.43 (s, 1H,
NH), d 1.43–1.13 (d, 2H, CH2);
13C NMR (100 MHz,
DMSO-d6): d 152.30, 150.60, 133.94, 127.79, 124.58, 117.90,
99.22, 40.70, 40.43, 40.23, 40.02, 39.81, 39.60, 39.39, 39.18,
36.28; Mass: 551.4 (5.25) (M+H)+, 381 (100%), 397.1
(78.04), 399 (53.07); Anal. Calcd. for C31H45ClN8: C, 65.88;
H, 8.03; N, 19.83. Found: C, 65.70; H, 8.09; N, 19.98.
4.6.5. N2-(3-(7-Chloroquinolin-4-ylamino)propyl)-N4,N6-
bis(4-morpholinophenyl)-1,3,5-triazine-2,4,6-triamine (6e)
%Yield: 58.33; mp: 258–260 C; UV kmax (DMSO): 260.5 nm;
FTIR (cm1): 3294 (N–Hstretch, >NH), 2922 (C–Hstretch,
>CH2), 2853 (C–Hstretch), 1579 (N–Hbend), 1451
(>C‚C<stretch), 1367, 1207, 1136 (C–Hstretch), 852 (C–Hstretch
out of plane), 807, 645 (C–Hbend);
1H NMR (400 MHz, DMSO-
d6): d 8.37 (d, 1H, quinolyl), d 8.28–8.25 (d, 1H,
J= 12.00 Hz, quinolyl), d 7.74 (d, 1H, quinolyl), d 7.45 (d,
1H, quinolyl), d 6.83 (s, 1H, morpholine), d 6.48 (d, 1H, Ar–
H), d 3.71 (s, 2H, CH2), d 3.43 (s, 2H, CH2), d 2.99 (s, 1H,
NH), d 2.48 (s, 1H, NH), d 2.07–2.03 (d, 2H, phenyl); 13C
NMR (100 MHz, DMSO-d6): d152.31, 127.91, 124.55, 40.58,
S630 H.R. Bhat et al.40.37, 40.16, 39.95, 39.75, 39.54, 39.33; Mass: 667.2 (3.06)
(M+H)+, 353.3 (100), 381.3 (61.98), 711.6 (4.26); Anal. Calcd.
for C35H39ClN10O2: C, 63.01; H, 5.89; N, 20.99. Found: C,
63.10; H, 6.01; N, 20.74.
4.6.6. N2-(3-(7chloroquinolin-4-ylamino)propyl)-N4,N6-bis(3-
chloro-4-ﬂuorophenyl)-1,3,5-triazine-2,4,6-triamine (6f)
%Yield: 46.78; mp: 202–204 C; UV kmax (DMSO): 262.0 nm;
FTIR (cm1): 3413, 3271 (N–Hstretch>NH), 3106 (C–Hstretch),
2929 (C–Hstretch, >CH2), 1581 (N–Hbend), 1493
(>C‚C<stretch), 1415, 1259, 1210, 1135 (C–Hstretch), 1054
(C–Nstretch), 870 (C–Hstretch out of plane), 807, 699 (C–Hbend out
of plane), 653 (C–Hbend), 576, 554, 513;
1H NMR (400 MHz,
DMSO-d6): d 8.53–8.34 (d, 1H, J= 78.00 Hz, quinolyl), d
8.30–8.28 (d, 1H, J= 9.20 Hz, quinolyl), d 8.09 (s, 1H, quino-
lyl), d 8.02 (s, 1H, quinolyl), d 7.75–7.73 (d, 1H, J= 8.80 Hz,
quinolyl), d 7.71–7.68 (d, 1H, J= 13.60 Hz, quinolyl), d 7.61
(s, 2H, NH), d 7.42–7.39 (d, 1H, J= 10.40 Hz, quinolyl), d
7.34–7.33 (d, 1H, J= 4.40 Hz, quinolyl), d 7.28–7.20 (m,
1H, quinolyl), d 6.46 (s, 2H, phenyl), d 3.41–3.36 (d, 2H,
J= 19.20 Hz, CH2), d 2.47 (s, 1H, NH), d 1.16–0.787 (d,
2H, J= 151.20 Hz, CH2);
13C NMR (100 MHz, DMSO-d6):
d166.03, 164.35, 164.19, 153.92, 151.52, 151.17, 151.10,
150.06, 148.15, 137.99, 136.58, 134.42, 126.83, 124.80, 124.36,
121.47, 120.38, 119.39, 119.21, 117.68, 116.93, 116.72, 99.04,
40.74, 40.36, 40.15, 39.94, 39.73, 39.52, 39.32, 38.51, 28.17;
Mass: 601.1 (M+H)+; Anal. Calcd. for C27H21Cl3F2N8: C,
53.88; H, 3.52; N, 18.62. Found: C, 54.00; H, 3.11; N,
18.48.
4.6.7. N2-(3-(7-chloroquinolin-4-ylamino)propyl)-N4,N6-bis(4-
ﬂuorophenyl)-1,3,5-triazine-2,4,6-triamine (6g)
%Yield: 55.56; mp: 183–185 C; UV kmax (DMSO): 261.0 nm;
FTIR (cm1): 3265 (N–Hstretch, >NH), 3108, 2930 (C–Hstretch,
>CH2), 1617, 1582 (N–Hbend), 1502, 1415, 1209, 1154 (C–
Hstretch), 984, 832 (C–Hstretch out of plane), 787 (C–Hbend out of
plane), 542, 510;
1H NMR (400 MHz, DMSO-d6): d 8.81–8.72
(d, 1H, J= 35.60 Hz, quinolyl), d 8.55–8.52 (d, 1H,
J= 14.00 Hz, quinolyl), d 8.40–8.36 (d, 1H, J= 12.40 quino-
lyl), d 7.88 (s, 1H, quinolyl), d 7.73–7.66 (d, 1H, J= 30.80 Hz,
quinolyl), d 7.52–7.50 (d, 1H, J= 6.80 Hz, quinolyl), d 7.20–
7.17 (d, 1H, J= 13.20 Hz, quinolyl), d 7.14–7.11 (d, 1H,
J= 10.80 Hz, quinolyl), d 7.07 (s, 2H, NH), d 7.04–7.00 (m,
1H, quinolyl), d 6.30 (s, 2H, phenyl), d 6.62–6.60 (d, 1H,
J= 5.60 Hz, phenyl), d 3.72 (s, 1H, NH), d 3.47–3.46 (d,
2H, J= 2.40 Hz, CH2), d 3.43–3.40 (dd, 2H,
J= 4.00,5.60 Hz, CH2), d 2.47 (s, 1H, NH), d 2.04–1.97 (d,
2H, J= 27.20 Hz, CH2), d 1.15 (s, 1H, NH);
13C NMR
(100 MHz, DMSO-d6): d 166.12, 164.46, 164.35, 156.54,
153.44, 147.03, 143.55, 137.09, 136.35, 125.91, 125.71, 124.16,
123.58, 123.10, 121.99, 116.83, 115.76, 115.53, 115.29, 115.08,
98.95, 95.87, 41.01, 40.58, 40.37, 40.16, 39.95, 39.53, 39.32,
38.20, 28.05; Mass: 533.2 (33.19) (M+H)+, 377.2 (100),
535.2 (13.62), 536.2 (3.97); Anal. Calcd. for C27H23ClF2N8:
C, 60.85; H, 4.35; N, 21.02. Found: C, 60.60; H, 4.51; N, 20.98.5. Conclusion
On close perlustration and analysis, all the target compounds
exhibit mild to moderate degrees of parasite inhibition. But,
none of the compounds proved to be as effective as lead,although it contains 1,3,5-traizine and 4-aminoquinoline which
already proved be an effective pharmacophore present in clin-
ically used drugs such as cycloguanil and chloroquine, respec-
tively. The present study illustrates that the existence of these
two active pharmacophoric groups could not translate hybrid
molecules into potent antimalarials. In the light of the above,
our further studies are in progress to explain the plausible
mechanism lying behind this untoward activity.
However, it can be concluded that this class of compounds
will certainly hold a great promise by effective pharmacomod-
ulation toward pursuit to discover a novel class of antimalarial
agents to substitute expensive ACTs in the near future.
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